Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1

Official title

Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study

Overview

The goal of this clinical trial is to learn whether brain stimulation technology can help people reach a meditative state quickly and easily without years of meditation training. The researchers want to see if this will help people distance themselves from their thoughts and feeling, and if this will lead to improvements in openness and wellbeing the same way meditation can. Participants will: * Complete questionnaires * Perform a guided meditation task (The Bell Task) * Wear a high density electrocochleography (hdEEG) cap * Undergo brain stimulation * Perform cognitive tasks

Detailed description

This study is being done to evaluate the relative effectiveness of distinct types of non-invasive brain stimulation - NIBS (TES-TI and TES) on subjective ego disengagement and cortical activity in experienced meditators.

Phase 1 (registered to this record) involves administering 2 distinct types of deep brain stimulation techniques to a small sample (N=22) of experienced meditators to determine which type of neuromodulation, when focused on disruption of posteromedial cortex (PMC) activity, most robustly facilitates positive ego-disengagement compared to sham; and to discern the region of the PMC where disruption is most effective in achieving ego disengagement.

Phase 2 (registered to a separate record, NCT06601699) will use the most effective stimulation and PMC parameters to meditation naïve healthy adults.

Interventions

• Device Transcranial electrical stimulation (TES)
  TES uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES.
• Device Transcranial electrical stimulation with temporal interference (TES-TI)
  TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.
• Device Sham stimulation
  TES-TI sham includes receiving stimulation from all electrodes at the same frequency. Sham TES will include administration of transcranial random noise stimulation (tRNS), random oscillating current. It will also include periods with no stimulation and a ramping up period followed by no stimulation.

Primary outcome measures

• Ego-Disengagement scale [Time frame: Data collected at one study visit (anytime up to 2 weeks on study)]
• Cortical activity - change in gamma band power [Time frame: Data collected at one study visit (anytime up to 2 weeks on study)]
• Cortical activity - change in alpha band power [Time frame: Data collected at one study visit (anytime up to 2 weeks on study)]

Secondary outcome measures (12)

• Big Five Aspects Scale (BFAS) [Time frame: Data collected at one study visit (anytime up to 2 weeks on study)]
• Fulfilled Life Scale (FLS) [Time frame: Data collected at one study visit (anytime up to 2 weeks on study)]
• Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety [Time frame: Data collected at one study visit (anytime up to 2 weeks on study)]
• PROMIS Depression [Time frame: Data collected at one study visit (anytime up to 2 weeks on study)]
• Perceived Stress Scale (PSS) [Time frame: Data collected at one study visit (anytime up to 2 weeks on study)]
• Questionnaire for Eudaimonic Well-Being (QEWB) [Time frame: Data collected at one study visit (anytime up to 2 weeks on study)]
• Psychological Wellbeing Scale (PWB) [Time frame: Data collected at one study visit (anytime up to 2 weeks on study)]
• IQSS Flourishing Measure [Time frame: Data collected at one study visit (anytime up to 2 weeks on study)]
• Metacognitive Processes of Decentering Scale (MPoD) [Time frame: Data collected at one study visit (anytime up to 2 weeks on study)]
• Experiences Questionnaire (EQ) [Time frame: Data collected at one study visit (anytime up to 2 weeks on study)]
• Self-Reflection Insight Scale (SRIS) [Time frame: Data collected at one study visit (anytime up to 2 weeks on study)]
• Non-Attachment Scale (NAS) [Time frame: Data collected at one study visit (anytime up to 2 weeks on study)]

Eligibility criteria

Inclusion criteria

• Adults, ages 18 to 80 of any identified gender
• Medically healthy
• English-speaking (able to provide consent and complete questionnaires)
• Healthy adults with a consistent meditation practice
• Citizen or legal resident

Exclusion criteria

• Any current or past history of neurological disorders or acquired neurological disease (e.g. stroke, traumatic brain injury), including intracranial lesions
• Any current or past history of bipolar disorder and/or hypomania
• Any current or past history of psychosis
• History of head trauma resulting in prolonged loss of consciousness; or a history of greater than 3 grade I concussions
• Current history of poorly controlled headaches including intractable or poorly controlled migraines
• Any systemic illness or unstable medical condition that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)
• History of fainting spells of unknown or undetermined etiology that might constitute seizures
• History of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG, or family history of treatment resistant epilepsy with the exception of a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist
• Possible pregnancy. All female participants of child-bearing age are required to have a pregnancy test
• Any metal in the brain, skull or head
• Any contraindications to MRI
• Any medical devices or implants (i.e. cardiac pacemaker, medication infusion pump, cochlear implant, vagal nerve stimulator, dental implants (this includes a permanent retainer)) unless otherwise approved by the responsible MD
• Substance abuse or dependence within the past six months
• Any medication that may alter seizure threshold i.e., ADHD stimulants (Adderall, amphetamine); Tricyclic/atypical antidepressants (Amitriptyline, Dioxepine, Imipramine Maprotiline, Nortriptyline, Bupropion); Antipsychotics (Chlorpromazine, Clozapine), Bronchodilators (theophylline, aminophylline); Antibiotics (fluoroquinolones, imipenem, penicillin, cephalosporins, metronidazole, isoniazid); Antiviral (Valacyclovir, Ritonavir); OTC (Diphenhydramine)
• Claustrophobia (a fear of small or closed places)
• Back problems that would prevent lying flat for up to two hours
• Motion sickness
• Any hair braid, dreadlocks, hair pieces, or extensions which cannot be taken out or adjusted to permit comfortable and comprehensive participation before the MRI scans and/or stimulation sessions
• Any head coverings or headdress that participant feels uncomfortable removing for the purposes of the MRI scans and/or stimulation session

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Basic science

Study locations

United States · 1 center

• University of Wisconsin — Madison

Identifiers

NCT: NCT06601686 · 2023-0613 · A535100 · Protocol Version 4/10/26

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗